PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer - European Medical Journal

PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer

Oncology

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) summarises the status of poly (ADP-ribose) polymerase (PARP) inhibitors in preclinical and clinical development for the treatment of breast cancer. Prof. Dr. med. Fasching explains the design of the EMBRACA study, which is a 2:1 randomised phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.

This programme is supported by BioMarin Pharmaceutical.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now